Search Results 1-10 of 11092 for ������������KA���:ZA31���24������ ���������������������������������
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The purpose of this study is to evaluate the safety and tolerability of ART24 after 7 or 28 days of daily administration in recently-cured C. diff infection ...
unexplained cough for which an underlying condition has not been determined despite adequate investigation with diagnostic tests and trials of therapy.
... 24-hour cough frequency in an enriched population of adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks. Participation ...
First, by comparison to simultaneously recorded video-EEG in the epilepsy monitoring unit (gold standard). Second, by comparison to self-reported seizure log ...
This study is being conducted to examine survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with ...
Dosing · Adults—10 milligrams (mg) 3 or 4 times for the first 24 hours, then 5 mg 3 to 4 times per day as needed. · Older adults—At first, 2 to 2.5 mg 1 or 2 ...
"The CYP24A1 gene, encoding the vitamin D 24-hydroxylase, is of major clinical and physiologic importance because it also serves to regulate the catabolism of 1 ...
24. Presenting Evidence in Investigations ... 24. Respondent Acceptance of Responsibility ...
Accessed Jan. 24, 2022. Holter and event monitors. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/holter-and-event-monitors.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.